<unk>  sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory<unk>  and the opioid<unk>  used for the management and treatment of pain. Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.
Celecoxib/tramadol
Ibuprofen/paracetamol
Amlodipine/celecoxib
Naproxen/diphenhydramine
Phenylephrine/ketorolac
Hydrocodone/ibuprofen
Hydrocodone/aspirin
Oxycodone/ibuprofen